The Debate Surrounding Whole Genome Sequencing in Disease Diagnosis

Introduction to Whole Genome Sequencing

The use of whole genome sequencing (WGS) as a diagnostic and predictive tool for disease risk is a subject of considerable debate. Recent clinical trials have revealed that approximately one in five healthy adults may unknowingly possess variations in genes associated with disease susceptibility.

Potential Benefits of Whole Genome Sequencing

Whole genome sequencing involves mapping an individual’s complete DNA profile. Proponents argue that the insights gained from WGS could revolutionize medical practice by fostering a new branch of medicine focused on preventative care and personalized health strategies.

Concerns About Genetic Information

Conversely, critics highlight that the significance of many genetic variations remains unclear. Consequently, the American College of Medical Genetics and Genomics (ACMG) advises that only results from 59 genes known to be linked to disease should be reported.

Insights from Clinical Trials

Despite ongoing debates, recent clinical trials assessing WGS in healthy adults were featured in a Science news article. The first trial involved a randomized study with 100 healthy adults who shared their family medical histories with their primary care physicians. Out of these, whole genome sequencing was conducted on 50 individuals, analyzing five million single nucleotide variants across 4,600 genes. Although the potential risk for polygenic diseases was also examined, these findings were not elaborated upon in the study.

The second trial, which remains unpublished, focused on whole exon sequencing in a group of 70 healthy adults.

Findings from the First Trial

The initial trial uncovered at least one genetic alteration linked to disease susceptibility in 11 participants, with two exhibiting evident symptoms. Furthermore, every sequenced individual had at least one recessive alteration associated with a disease, which is significant for family planning as two copies of such alterations are required to manifest a disease. Notably, 34% of the sequenced individuals were referred to genetic counseling or underwent further laboratory tests, compared to 16% of those who were not sequenced. Additionally, sequenced participants incurred an extra $350 in healthcare expenses.

Emotional impacts, such as anxiety and depression, were not reported in either group six months post-study, and many participants utilized the information to adapt their health behaviors.

Results from the Second Trial

The second trial mirrored the first in that it detected at least one alteration linked to increased disease risk in 12 participants, representing 17% of the group.

Implications for Genetic Screening Recommendations

Although both studies were limited in size and require further validation, they suggest that the ACMG may need to reevaluate its recommendations regarding the number of disease-associated genes included in standard genetic screening tests.

Future Considerations and Challenges

The findings from these trials indicate that the insights gained from whole genome sequencing could be invaluable to healthcare providers. Some advocates propose that WGS should be integrated into primary care practices. However, concerns about escalating medical and insurance costs persist, especially given that the first trial incurred a cost of $5,000 for a single whole-genome sequence. Additionally, the psychological, economic, and emotional effects of this genetic information remain uncertain.

Conclusion

Despite the controversies, the revelation that roughly 20% of the population may unknowingly carry genetic variations associated with disease susceptibility adds significant weight to the ongoing discussions surrounding whole genome sequencing.

References

Cross, R. One in five “healthy” adults may carry disease-related genetic mutations. Biology Health. 2017. Available at: doi: 10./science.aan7017.